Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer - PubMed (original) (raw)
. 2003 Jul 30;22(14):2239-56.
doi: 10.1002/sim.1430.
Affiliations
- PMID: 12854091
- DOI: 10.1002/sim.1430
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer
Patrick Royston et al. Stat Med. 2003.
Abstract
With the increasing pace of drug development, it is not unusual for several promising treatment regimens to be ready simultaneously for testing in a randomized phase III setting. Various limiting factors, including the time needed to transfer research results to clinical practice and a narrow 'window of opportunity', may make it unfeasible to perform trials to test such regimens sequentially against a control treatment in a traditional two-arm parallel group design. We present an approach to trial design based on eliminating inferior contenders at an early stage, allowing through to a second stage only treatments that show a predefined degree of advantage against a control treatment. The first stage of testing utilizes a marker known to be a valid intermediate outcome measure or surrogate for the definitive outcome. The experimental arms are compared pairwise with control according to this intermediate outcome measure. Arms that survive the comparison enter a second stage of patient accrual culminating in comparisons against control on the outcome measure of primary interest. We show how the design may be realized in practice by considering hypothetically distinct trials at stages 1 and 2, each with their own operating characteristics. The overall operating characteristics are computed from the stage 1 and 2 size and power and the correlation between the treatment effects on the intermediate and primary outcome measures according to a bivariate Normal approximation. The correlation is estimated by bootstrapping individual patient data from previous trials. We illustrate the general approach in a design of a real trial of four new chemotherapy regimens for advanced ovarian cancer. The intermediate outcome measure is progression-free survival. An international randomized controlled trial using the new design is already under way.
Copyright 2003 John Wiley & Sons, Ltd.
Similar articles
- Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Llovet JM, et al. J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. J Natl Cancer Inst. 2008. PMID: 18477802 Review. - Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Pfisterer J, et al. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45. doi: 10.1093/jnci/djj296. J Natl Cancer Inst. 2006. PMID: 16882940 Clinical Trial. - Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C. Panici PB, et al. J Natl Cancer Inst. 2005 Apr 20;97(8):560-6. doi: 10.1093/jnci/dji102. J Natl Cancer Inst. 2005. PMID: 15840878 Clinical Trial. - Interim futility analysis with intermediate endpoints.
Goldman B, LeBlanc M, Crowley J. Goldman B, et al. Clin Trials. 2008;5(1):14-22. doi: 10.1177/1740774507086648. Clin Trials. 2008. PMID: 18283075 - Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA, Bentzen SM, Chen EX, Siu LL. Tang PA, et al. J Clin Oncol. 2007 Oct 10;25(29):4562-8. doi: 10.1200/JCO.2006.08.1935. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876010 Review.
Cited by
- Integrated phase II/III clinical trials in oncology: a case study.
Wang M, Dignam JJ, Zhang QE, DeGroot JF, Mehta MP, Hunsberger S. Wang M, et al. Clin Trials. 2012 Dec;9(6):741-7. doi: 10.1177/1740774512464724. Epub 2012 Nov 22. Clin Trials. 2012. PMID: 23180870 Free PMC article. Review. - Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
Royston P, Barthel FM, Parmar MK, Choodari-Oskooei B, Isham V. Royston P, et al. Trials. 2011 Mar 18;12:81. doi: 10.1186/1745-6215-12-81. Trials. 2011. PMID: 21418571 Free PMC article. - Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
Blenkinsop A, Parmar MK, Choodari-Oskooei B. Blenkinsop A, et al. Clin Trials. 2019 Apr;16(2):132-141. doi: 10.1177/1740774518823551. Epub 2019 Jan 16. Clin Trials. 2019. PMID: 30648428 Free PMC article. - Evaluating many treatments and biomarkers in oncology: a new design.
Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, Parmar M. Kaplan R, et al. J Clin Oncol. 2013 Dec 20;31(36):4562-8. doi: 10.1200/JCO.2013.50.7905. Epub 2013 Nov 18. J Clin Oncol. 2013. PMID: 24248692 Free PMC article. - Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate.
Wason JMS, Robertson DS. Wason JMS, et al. Pharm Stat. 2021 Jan;20(1):109-116. doi: 10.1002/pst.2059. Epub 2020 Aug 12. Pharm Stat. 2021. PMID: 32790026 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical